Faculty Profile, National Health Research Institutes, Taiwan

Faculty Profiles

Gi-Ming Lai, M.D.

Associate Investigator and Attending Physician
Director, Office of Hospital Cooperation
National Institute of Cancer Research


M.D., College of Medicine, National Taiwan University, Taiwan,1978


  • Director, Office of Collaborative Medical Affairs, National Health Research Institutes, Taiwan (2007-2008)

  • Director, Department of Administration, National Health Research Institutes, Taiwan (2004-2007)

  • Associate Investigator and Attending Physician, National Institute of Cancer Research, National Health Research Institutes, Taiwan (2004-present)

  • Director, Taiwan Cooperative Oncology Group, National Health Research Institutes, Taiwan (1997-2002)

  • Senior staff, Cancer Collaborative Ward, National Taiwan University Hospital/National Health Research Institutes, Taiwan (1997-2002)

  • Chief Executive Officer, Formosa Cancer Foundation (1997-present)

  • Associate Professor of Chinese Medical Science, ChinaMedicalUniversity (1995-present)

  • General Secretary, the Chinese Oncology Society

  • Associate Professor of Medicine, Chang Gung Medical College, Taiwan (1990-1996)

  • Co-Director, Preparing Office for Chang Gung Memorial Tumor Institute, Taiwan (1989-1996)

  • Visiting Associate, Experimental Therapeutics Section, Medicine Branch, COP, DCT, NCI, NIH, USA (1987-1989)

  • Medical Staff, Department of Internal Medicine, Division of Hematology-Oncology, CGMH (1982-1996)


In addition to the expertise in clinical trial, Dr. Lai’s research interest is to look for more efficacious cancer therapy by combining drugs or seeking active ingredients of natural products from which are regarding as Complementary and Alternative Medicine (CAM). Dr. Lai evaluates those candidates by examining their molecular targeting effects in the aspects of differentiation induction, cell cycle regulation, signal transduction inhibition, reversal of drug resistance, and chemoprevention.


In search of more efficacious cancer therapy, Dr. Lai had found that combining mevalonate pathway inhibitor “lovastatin” with peroxisome proliferator-activated receptor Y (PPAR Y) agonist “troglitazone” or with alcoholic extract of Antrodia camphorata could exert synergistic anticancer effects in various types of cancer cells. The U.S. patent applications for these two findings are pending. (Patent Application
Publication, Pub. No.: US 2005/0209292 A1). His study also demonstrated the mechanisms responsible for anticancer effects of the human urinary extract “CDA-2” were majorly related to molecular targeting, such as induction of differentiation and apoptosis, cell cycle regulation, signal transduction inhibition, antiangiogenesis, and reversal of chemo-resistance, and radio-resistance. CDA-2 had been approved as a first class new anti-cancer drug by the SFDA of mainland China in 2004 through the effort of both sides of Taiwan Strait.


  1. Lai JD, Hong CC, Huang JS, Yang YY, Pao CY, Liu CH, Lai YP, Lai GM, Cheng AL, Su IJ and Chuang SE. Sulfasalazine suppresses drug resistance and invasiveness of AXL-expressing lung adenocarcinoma cells through inhibition of NF-κB. [2007 accepted]

  2. Chen CN, Huang HH, Wu CL, Lin CP, Hsu JT, Hsieh HP, Chuang SE and Lai GM. Isocostunolide, a sesquiterpene lactone, induces mitochondrial membrane depolarization and caspase-dependent apoptosis in human melanoma cells. Cancer Letter, 246(1-2): 237-52, 2006.*

  3. Yao CJ, Lai GM, Chan CF, Cheng AL, Yang YY and Chuang SE. Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone. Int J Cancer, 118(3):773-9, 2006.

  4. Yao CJ, Lai GM, Chan CF, Yang YY, Liu FC and Chuang SE. Differentiation of pheochromocytoma PC12 cells induced by human urine extract and the involvement of the extracellular signal-regulated kinase signaling pathway. J Altern Complement Med, 11(5):903-8, 2005.

  5. Yan MD, Hong CC, Lai GM, Cheng AL, Lin YW and Chuang SE. Identification and characterization of a novel gene Saf transcribed from the opposite strand of Fas. Hum Mol Genet, 14(11):1465-74, 2005.

  6. Chuang SE, Yeh PY, Lu YS, Lai GM, Liao CM, Gao M and Cheng AL. Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. Biochem Pharmacol, 63(9):1709-1716, 2002.

  7. Putti TC, To KF, Hsu HC, Chan ATC, Lai GM, Tse G, Lee YS, Whang-Peng J, Millward M, Lin L and Lee CS. Expression of epidermal growth factor receptor in head and neck cancers correlates with clinical progression: a multicentre immunohistochemical study in the Asia-Pacific region. Histopathology, 41:144-151, 2002.

(* = Corresponding Author)


US 0209292A1 "Cancer Therapy" ; 2005